Richard V, de Leiris J
Adv Myocardiol. 1985;6:563-72.
The ability of intravenous or oral bepridil to reduce infarct size was studied in the rat submitted in situ to coronary-artery ligation. Infarct size was measured by planimetry of serial 8-micron sections at known intervals 48 hr after left-coronary-artery ligation. Succinate dehydrogenase activity (nitroblue tetrazolium stain) was used as an index of tissue viability. Bepridil was administered either intravenously (5 mg/kg) 15 min before (pretreatment) or 10 min after (post-ligation treatment) coronary-artery ligation, or orally (50 mg/kg per day) for 8 days before coronary ligation. Intravenous bepridil pretreatment reduced infarct size by more than 30%. This reduction was accompanied by a better preservation of the myocardial content of adenine nucleotides and a reduction in lactate accumulation. Intravenous post-ligation treatment and chronic oral treatment induced a reduction in infarct size similar to the one observed with intravenous preligation treatment. Thus, bepridil is equipotent in reducing infarct size whether the drug is administered intravenously before or after coronary-artery occlusion, or orally before coronary occlusion.
在原位进行冠状动脉结扎的大鼠中，研究了静脉注射或口服苄普地尔减小梗死面积的能力。梗死面积通过在左冠状动脉结扎48小时后，以已知间隔对连续的8微米切片进行平面测量来测定。琥珀酸脱氢酶活性（硝基蓝四氮唑染色）用作组织活力的指标。苄普地尔在冠状动脉结扎前15分钟（预处理）或结扎后10分钟（结扎后治疗）静脉注射（5毫克/千克），或在冠状动脉结扎前8天口服（每天50毫克/千克）。静脉注射苄普地尔预处理可使梗死面积减小超过30%。这种减小伴随着腺嘌呤核苷酸心肌含量的更好保存以及乳酸积累的减少。静脉注射结扎后治疗和慢性口服治疗导致梗死面积减小，类似于静脉注射结扎前治疗所观察到的情况。因此，无论在冠状动脉闭塞前还是后静脉给药，或者在冠状动脉闭塞前口服给药，苄普地尔在减小梗死面积方面具有同等效力。
